Human Influenza Clinical Trial
Official title:
Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults 18 Years of Age and Older
The primary objective of this study is to retrospectively characterize the safety of Flublok in adults 18 years of age and older, in comparison with egg-based trivalent or quadrivalent inactivated influenza vaccines (IIVs), using a methodological approach designed to query the database of electronic health records (EHR) maintained by Kaiser-Permanente, Northern California (KPNC), a large medical care organization (MCO).
The primary analysis is a nonrandomized, observational retrospective cohort study. Data on adults 18 years of age and older who were enrolled in the KPNC database during the risk intervals after vaccination analyzed for this study who were vaccinated with Flublok or an IIV (either IIV3 or IIV4) will be identified for analysis. The rates of occurrence of specific MAEs of interest in pre-specified risk intervals following Flublok and IIV will be compared. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01690637 -
Panama and El Salvador Children's Oseltamivir Study
|
Phase 4 | |
Completed |
NCT03572491 -
Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine
|
Phase 3 | |
Recruiting |
NCT04487041 -
Tfh Dysfunction in HIV and Aging
|
Phase 4 | |
Completed |
NCT02387294 -
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
|
Phase 3 | |
Completed |
NCT01511744 -
Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine
|
Phase 4 | |
Completed |
NCT02398097 -
Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects
|
Phase 4 | |
Completed |
NCT01342796 -
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
|
Phase 2 | |
Completed |
NCT01677702 -
Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization
|
N/A | |
Active, not recruiting |
NCT01096225 -
Immunogenicity Study of S-OIV H1N1 Influenza Vaccine
|
N/A | |
Completed |
NCT00880659 -
Bangladesh Secondary Transmission Handwashing Protocol
|
Phase 2 | |
Completed |
NCT01879553 -
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above
|
Phase 2 | |
Completed |
NCT01879540 -
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
|
Phase 2 | |
Completed |
NCT01636102 -
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
|
Phase 2 | |
Completed |
NCT01651104 -
Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
|
Phase 2 | |
Completed |
NCT03448705 -
Safety of 4Fluart ID Suspension for Injection in Adult Subjects
|
Phase 1 | |
Completed |
NCT02478905 -
Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting
|
N/A | |
Recruiting |
NCT04431050 -
Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
|
||
Completed |
NCT01568788 -
Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine
|
N/A | |
Completed |
NCT05155319 -
Universal Influenza A Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT01885117 -
Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above
|
Phase 3 |